| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
H-Hyp-OMe·HCl does not have a specific biological target as a drug. Its primary utility is as a chemical linker in the synthesis of antibody-drug conjugates (ADCs) and PROTACs (PROteolysis TArgeting Chimeras). In ADCs, the linker connects the antibody to the cytotoxic drug. In PROTACs, the linker connects two ligands to induce targeted protein degradation. It does not have a therapeutic target but is a key component in the design of these therapeutic modalities.
|
|---|---|
| ln Vitro |
ADC cytotoxins are connected to antibodies through an ADC connector to form ADCs [1]. Two distinct ligands, one for the E3 ubiquitin ligase and the other for the target protein, are present in PROTAC and are joined by a linker. PROTAC selectively degrades target proteins by means of the intracellular ubiquitin-proteasome system [2].
H-Hyp-OMe·HCl does not exhibit pharmacological activity in vitro. As a chemical linker, it is a synthetic intermediate rather than a bioactive compound. In vitro studies using this compound focus on its chemical reactivity in the synthesis of ADCs and PROTACs. The compound's utility is in the conjugation of antibodies to drugs or ligands to targeting moieties. Its role in research is as a reagent for bioconjugation and drug delivery. |
| ln Vivo |
H-Hyp-OMe·HCl is not a pharmacologically active compound and therefore does not have defined in vivo activity as a drug. Its primary value is as a chemical linker in the synthesis of ADCs and PROTACs. When used in the synthesis of ADCs, the final conjugate may have therapeutic activity, but the linker itself is not active. It is not intended for in vivo administration in its unconjugated form.
|
| Enzyme Assay |
In vitro assays for H-Hyp-OMe·HCl are focused on its chemical properties and reactivity in the synthesis of ADCs and PROTACs. Standard protocols involve the use of this compound as a linker in conjugation reactions. The compound is typically dissolved in organic solvents such as DMSO and coupled to antibodies or other targeting moieties using standard bioconjugation chemistry. The progress of the conjugation reaction can be monitored by HPLC or mass spectrometry.
|
| Cell Assay |
In vitro cellular assays using H-Hyp-OMe·HCl are not performed, as the compound is a chemical linker used in synthesis rather than a bioactive molecule. However, the ADCs or PROTACs synthesized using this linker may be tested in cellular assays to evaluate their activity. The compound itself is not designed for cell culture studies and its use is confined to the laboratory for chemical synthesis.
|
| Animal Protocol |
In vivo animal studies with H-Hyp-OMe·HCl are not conducted, as the compound is a chemical linker rather than a pharmacologically active agent. However, the ADCs or PROTACs synthesized using this linker may be evaluated in animal models to assess their efficacy and safety. The linker itself is not administered in vivo.
|
| ADME/Pharmacokinetics |
H-Hyp-OMe·HCl is not a drug candidate, and pharmacokinetic data are not available for the compound itself. As a chemical linker, it is designed for use in synthesis rather than systemic administration. The pharmacokinetic properties of the final ADC or PROTAC conjugate would be determined by the properties of the entire molecule.
|
| Toxicity/Toxicokinetics |
H-Hyp-OMe·HCl is generally considered to have low toxicity, consistent with its use as a chemical reagent. It is a hydrochloride salt of a protected amino acid. Standard laboratory safety precautions, including the use of personal protective equipment, are recommended. It is not classified as a highly toxic substance, but appropriate safety measures should be followed.
|
| References | |
| Additional Infomation |
H-Hyp-OMe·HCl (trans-4-Hydroxy-L-proline methyl ester hydrochloride, CAS 40216-83-9) is a protected derivative of hydroxyproline. Its molecular formula is C₆H₁₂ClNO₃ and its molecular weight is 181.62 g/mol. It is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). It is also a PROTAC linker based on an alkyl chain. It is intended for research use only.
|
| Molecular Formula |
C6H11NO3.HCL
|
|---|---|
| Molecular Weight |
181.61738
|
| Exact Mass |
181.05
|
| CAS # |
40216-83-9
|
| PubChem CID |
11435319
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
247.2ºC at 760 mmHg
|
| Flash Point |
103.3ºC
|
| LogP |
0.013
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
11
|
| Complexity |
137
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O=C([C@H]1NC[C@H](O)C1)OC.[H]Cl
|
| InChi Key |
KLGSHNXEUZOKHH-JBUOLDKXSA-N
|
| InChi Code |
InChI=1S/C6H11NO3.ClH/c1-10-6(9)5-2-4(8)3-7-5;/h4-5,7-8H,2-3H2,1H3;1H/t4-,5+;/m1./s1
|
| Chemical Name |
methyl (2S,4R)-4-hydroxypyrrolidine-2-carboxylate;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.5060 mL | 27.5300 mL | 55.0600 mL | |
| 5 mM | 1.1012 mL | 5.5060 mL | 11.0120 mL | |
| 10 mM | 0.5506 mL | 2.7530 mL | 5.5060 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
